Table 1.
Summary of baseline characteristics
| Parameter | Morbidly obese group (n = 20) | Nonobese group (n = 8) |
|---|---|---|
| Weight (kg) | 139.0 (110.6–234.6) | 69.5 (60.0–84.7) |
| Height (cm) | 173.5 (159–189) | 182.5 (166–190) |
| BMI (kg m−2) | 45.5 (40.8–65.7) | 21.2 (20.4–25.0) |
| Age | 38.0 (23–54) | 25.5 (20–55) |
| Serum creatinine (μmol L−1)a | 72 (41–101) | 70 (60–86) |
| GFR (mL min−1) | 141.4 (80.7–260.7) | 117.9 (88.1–147.0) |
| MDRD (mL min−1) | 138.3 (89.5–220.6) | 115.4 (72.8–144.7) |
| CKD‐EPI (mL min−1) | 148.1 (95.5–221.6) | 125.3 (77.1–139.3) |
| CG‐TBW (mL min−1) | 249.2 (166.0–431.8) | 140.1 (87.9–157.3) |
| CG‐LBW (mL min−1) | 122.0 (83.1–191.0) | 140.1 (87.9–157.3) |
Data shown as median (range).
a
Serum creatinine as measured before administration of vancomycin.
BMI, body mass index; GFR, glomerular filtration rate measured using 24‐h creatinine clearance; MDRD, Modification of Diet in Renal Disease; CKD‐EPI, Chronic Kidney Disease Epidemiology Collaboration; CG‐TBW, Cockcroft–Gault (conventional); CG‐LBW, CG calculated with lean body weight instead of total body weight for obese.